CO-1686(Rociletinib) is an irreversible inhibitor of epidermal growth factor receptor (EGFR).CO-1686(Rociletinib) was used for EGFR-Mutated NonCSmall-Cell Lung Cancer.Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.)
Contact：Wuhan Sun-shineBio-technologyCorporation Limited Add: Building C16, No.388Gaoxin 2Road, East Lake Hi-tech Development Zone, Wuhan 430200, China Tel: +86-27-65522452 QQ：1973737790 Web:http://www.sun-shinechem.com
| 
-cas-1374640-70-6.png)